Friday, 23 Aug 2019

You are here

Upadacitinib Superior to Adalimumab in Methotrexate Refractory RA

Upadacitinib, a JAK1-selective inhibitor, was studied head to head against adalimumab (ADA) and placebo (PBO) in rheumatoid arthritis after an inadequate response to methotrexate, and shown to be superior to ADA and PBO in ACR20 and DAS remission level responses. 

A total of 1629 patients were randomized once-daily upadacitinib (UPA) 15mg, PBO or ADA 40mg, every other week while remaining on background methotrexate. Primary endpoints were ACR20 and DAS28CRP<2.6 versus placebo at Week12 and inhibition of radiographic progression was evaluated at Week26. 

UPA was superior to ADA and PBO at Week12:

  • ACR20: UPA 71% vs. ADA 64% vs. PBO 36%  (p≤0.001 UPA vs PBO; p< 0.5 UPA vs ADA).
  • DAS28CRP<2.6  UPA 29% vs. ADA 18% vs PBO 6%.
  • ACR50: UPA 45% vs. ADA 29% vs. PBO 15%
  • ACR70: UPA 25% vs. ADA 13% vs. PBO 5%
  • DAS28CRP≤3.2 (LDAS): UPA 71% vs. ADA 64% vs. PBO 36%

Radiographic progression was less and observed in fewer patients receiving upadacitinib versus placebo (mTSS PBO +0.92 vs UPA +0.24 vs. ADA +0.1 p≤0.001 UPA & ADA vs PBO).

There were no surprises with regard to adverse events (AEs) being similar between groups.

  • Serious infections UPA 1.8% vs ADA 1.5% vs PBO 0.8%.
  • There were more discontinuations in those on ADA vs UPA
  • Herpes zoster (UPA 0.8%; ADA 0.3%; PBO 0.5%)
  • CPK elevations were higher for UPA treated patients
  • Venous thromboembolic events: a total of 6 were reported [PBO 1; UPA 2; ADA 3]
  • Others: 3 malignancies, 5 MACE, and 4 deaths were reported, none on UPA.

In this short term trial UPA was more clinically effective than ADA and PBO and equally comparable to ADA in radiographic inhibition. As expected of a Janus kinas inhibitor there were more cases of herpes zoster and CPK elevations on UPA. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

A Multidimensional Definition of Remission

A study from Leeds suggests 'multi-dimensional remission' (MDR) can be seen in one-third of RA patients achieving DAS28-remission; such patients have better patient-reported outcome measures, making it an optimal goal, especially from a patient's perspective.

Good Pregnancy Outcomes for DMARD Exposed JIA Patients

A study of pregnancy outcomes in 98 women with juvenile idiopathic arthritis (JIA) who were exposed to DMARDs shows no increased risk of major adverse pregnancy outcomes.

A total of 152 pregnancies in 98 women with JIA and 39 pregnancies involving 21 male patients as partners were reviewed. The majority had a polyarticular JIA (61%). The average age at first pregnancy was 24.1 years, and their mean disease duration was 13.8 years.

Autoantibodies Don't Disappear With Remission in RA

Immunologic remission in rheumatoid arthritis, defined as the disappearance of anti-citrullinated protein antibodies and rheumatoid factor, was seen infrequently among patients achieving sustained clinical remission and did not correlate with the disappearance of symptoms, a long-term Dutch study found.

Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease

Serologic testing is the principal means of laboratory diagnosis of Lyme disease. Current recommendations include using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay, followed by a western immunoblot assay for specimens yielding positive or equivocal results. On July 29, 2019, the Food and Drug Administration cleared several Lyme disease serologic assays with new indications for use, allowing for an EIA rather than western immunoblot assay as the second test in a Lyme disease testing algorithm. Thus, serologic assays that utilize a second EIA in place of western immunoblot assay are acceptable alternatives for the serologic diagnosis of Lyme disease.

Trends in Inflammatory Arthritis Care in Germany

The German National Database (NDB) has reviewed their experience in the care and quality of life of inflammatory rheumatic disease patients snce 1993, showing improved use of metrics, improved outcomes and a changing profile of biologic and anti-rheumatic drug use.